NYSEARCA:PTHS • US1711262048
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PELTHOS THERAPEUTICS INC (PTHS).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-01 | Cantor Fitzgerald | Initiate | Overweight |
| 2026-03-20 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-03-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-27 | Piper Sandler | Initiate | Overweight |
| 2026-02-26 | Roth Capital | Maintains | Buy -> Buy |
| 2026-01-26 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-12-03 | Lake Street | Initiate | Buy |
| 2025-12-03 | HC Wainwright & Co. | Initiate | Buy |
| 2025-11-25 | Roth Capital | Initiate | Buy |
| 2025-11-14 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2025-09-02 | Oppenheimer | Initiate | Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | 16.795M | 62.043M 269.41% | 113.27M 82.57% | 170.35M 50.39% | 211.26M 24.02% | 247.07M 16.95% | 213.45M -13.61% | 221.8M 3.91% | 232.27M 4.72% | ||
| EBITDA YoY % growth | N/A | N/A | -30.145M | -22.811B -75,571.97% | 7.515B 132.94% | 42.055B 459.61% | 35.088M -99.92% | 45.594M 29.94% | 56.508M 23.94% | 63.036M 11.55% | 70.278M 11.49% | |
| EBIT YoY % growth | -6.862M -196.02% | N/A -2.53% | -32.43M -360.92% | -38.972M -20.17% | -4.176M 89.28% | 54.8M 1,412.30% | 60.758M 10.87% | 82.681M 36.08% | 60.749M -26.53% | 67.783M 11.58% | 74.841M 10.41% | |
| Operating Margin | N/A | N/A | -193.09% | -62.81% | -3.69% | 32.17% | 28.76% | 33.46% | 28.46% | 30.56% | 32.22% | |
| EPS YoY % growth | N/A | N/A | N/A -43.19% | -9.76 48.61% | -1.46 85.05% | 5.24 459.44% | 5.12 -2.43% | 6.79 32.65% | 8.69 28.07% | 9.35 7.63% | 9.88 5.67% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -3.34 -1,029.89% | -2.39 55.67% | -1.72 67.57% | -1.97 2.86% | -0.88 73.60% | -0.44 81.40% | -0.20 88.13% | -0.13 93.28% |
| Revenue Q2Q % growth | 10.654M | 14.939M | 18.145M 145.00% | 18.321M 95.13% | 21.665M 103.35% | 27.662M 85.17% | 30.335M 67.18% | 31.829M 73.73% |
| EBITDA Q2Q % growth | -6.936M | -4.998M | -2.448M 82.87% | -3.06M 68.51% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -11.603M -532.63% | -8.885M -175.04% | -6.654M 56.69% | -6.909M 42.44% | -3.431M 70.43% | -224.91K 97.47% | 1.187M 117.84% | 236.13K 103.42% |
All data in USD
12 analysts have analysed PTHS and the average price target is 58.29 USD. This implies a price increase of 153.42% is expected in the next year compared to the current price of 23.
The consensus EPS estimate for the next earnings of PELTHOS THERAPEUTICS INC (PTHS) is -3.34 USD and the consensus revenue estimate is 10.65M USD.
The consensus rating for PELTHOS THERAPEUTICS INC (PTHS) is 83.3333 / 100 . This indicates that analysts generally have a positive outlook on the stock.